Counterpoint Mutual Funds LLC Buys New Position in Azenta, Inc. $AZTA

Counterpoint Mutual Funds LLC bought a new stake in Azenta, Inc. (NASDAQ:AZTA) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 26,306 shares of the company’s stock, valued at approximately $556,000. Counterpoint Mutual Funds LLC owned approximately 0.06% of Azenta at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its position in shares of Azenta by 2,067.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock valued at $27,000 after buying an additional 765 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Azenta by 54.1% during the fourth quarter. Assetmark Inc. now owns 832 shares of the company’s stock valued at $28,000 after buying an additional 292 shares during the period. Osaic Holdings Inc. boosted its position in Azenta by 44.9% during the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after acquiring an additional 385 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in Azenta by 98.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock worth $46,000 after acquiring an additional 689 shares during the period. Finally, Van ECK Associates Corp grew its stake in Azenta by 141.2% in the 4th quarter. Van ECK Associates Corp now owns 1,585 shares of the company’s stock worth $53,000 after acquiring an additional 928 shares during the period. 99.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AZTA. Weiss Ratings lowered Azenta from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. Needham & Company LLC lowered their price objective on Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $39.50.

Azenta Price Performance

Shares of NASDAQ AZTA opened at $25.84 on Friday. Azenta, Inc. has a 1-year low of $15.93 and a 1-year high of $41.73. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -6.53 and a beta of 1.37. The business has a 50-day moving average of $22.11 and a 200-day moving average of $26.97.

Azenta (NASDAQ:AZTA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). Azenta had a positive return on equity of 1.23% and a negative net margin of 30.49%.The business had revenue of $144.79 million for the quarter, compared to analyst estimates of $148.47 million. During the same period last year, the company posted $0.01 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis.

Azenta Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.